Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study

Much evidence highlighted the role of interferon alpha (IFN-α) in systemic lupus erythematosus (SLE) and suggested its possible role in assessing disease activity. We measured serum IFN-α in Egyptian SLE patients in order to determine a cutoff value that can be used to distinguish patients from heal...

Full description

Bibliographic Details
Main Authors: A. Fayed, M.M. El Menyawi, M. Ghanema, O. Shaker, R. Elgohary
Format: Article
Language:English
Published: PAGEPress Publications 2020-11-01
Series:Reumatismo
Subjects:
Online Access:https://www.reumatismo.org/index.php/reuma/article/view/1308
_version_ 1818200118580477952
author A. Fayed
M.M. El Menyawi
M. Ghanema
O. Shaker
R. Elgohary
author_facet A. Fayed
M.M. El Menyawi
M. Ghanema
O. Shaker
R. Elgohary
author_sort A. Fayed
collection DOAJ
description Much evidence highlighted the role of interferon alpha (IFN-α) in systemic lupus erythematosus (SLE) and suggested its possible role in assessing disease activity. We measured serum IFN-α in Egyptian SLE patients in order to determine a cutoff value that can be used to distinguish patients from healthy controls and explored its clinical value in monitoring disease activity and different aspects of the disease, in particular lupus nephritis. This cross-sectional, case-control study was conducted on 59 SLE patients and 30 healthy controls. Serum IFN-α was measured in all participants using sensitive enzyme-linked immunosorbent assay (ELISA). SLE patients underwent assessment of disease activity using the SLE disease activity index-2000 (SLEDAI-2K) as well as an evaluation of proteinuria, complement C3 and C4, and serology. Patients with evidence of renal involvement underwent renal biopsy. The median serum IFN-α was 81.8 pg/mL (interquartile range [IQR] 63.4:102.4), which was significantly higher than in healthy controls (median 10.3 pg/mL [IQR 7.3:11.6]) (p<0.001). At serum level of 14.7 pg/mL, IFN-α has high sensitivity and specificity to discriminate SLE patients from controls, with high positive and negative predictive values. Serum IFN-α was not associated with markers of disease activity, clinical features and anti-double stranded DNA. Furthermore, it was not associated with markers of renal activity, including proteinuria, C3 and C4 complement factors and histopathology renal classes. Despite elevated levels of serum IFN-α in SLE patients, it is not possible to use it as a biomarker for disease activity.
first_indexed 2024-12-12T02:32:35Z
format Article
id doaj.art-081108488ad14596b096a79a35764e47
institution Directory Open Access Journal
issn 0048-7449
2240-2683
language English
last_indexed 2024-12-12T02:32:35Z
publishDate 2020-11-01
publisher PAGEPress Publications
record_format Article
series Reumatismo
spelling doaj.art-081108488ad14596b096a79a35764e472022-12-22T00:41:22ZengPAGEPress PublicationsReumatismo0048-74492240-26832020-11-0172310.4081/reumatismo.2020.1308Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control studyA. Fayed0M.M. El Menyawi1M. Ghanema2O. Shaker3R. Elgohary4Nephrology unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo UniversityRheumatology & Clinical Immunology unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo UniversityRheumatology & Clinical Immunology unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo UniversityMedical Biochemistry and Molecular Biology, Kasr Alainy School of Medicine, Cairo UniversityRheumatology & Clinical Immunology unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo UniversityMuch evidence highlighted the role of interferon alpha (IFN-α) in systemic lupus erythematosus (SLE) and suggested its possible role in assessing disease activity. We measured serum IFN-α in Egyptian SLE patients in order to determine a cutoff value that can be used to distinguish patients from healthy controls and explored its clinical value in monitoring disease activity and different aspects of the disease, in particular lupus nephritis. This cross-sectional, case-control study was conducted on 59 SLE patients and 30 healthy controls. Serum IFN-α was measured in all participants using sensitive enzyme-linked immunosorbent assay (ELISA). SLE patients underwent assessment of disease activity using the SLE disease activity index-2000 (SLEDAI-2K) as well as an evaluation of proteinuria, complement C3 and C4, and serology. Patients with evidence of renal involvement underwent renal biopsy. The median serum IFN-α was 81.8 pg/mL (interquartile range [IQR] 63.4:102.4), which was significantly higher than in healthy controls (median 10.3 pg/mL [IQR 7.3:11.6]) (p<0.001). At serum level of 14.7 pg/mL, IFN-α has high sensitivity and specificity to discriminate SLE patients from controls, with high positive and negative predictive values. Serum IFN-α was not associated with markers of disease activity, clinical features and anti-double stranded DNA. Furthermore, it was not associated with markers of renal activity, including proteinuria, C3 and C4 complement factors and histopathology renal classes. Despite elevated levels of serum IFN-α in SLE patients, it is not possible to use it as a biomarker for disease activity.https://www.reumatismo.org/index.php/reuma/article/view/1308Systemic lupus erythematosuslupus nephritisinterferon alpha (IFN-α).
spellingShingle A. Fayed
M.M. El Menyawi
M. Ghanema
O. Shaker
R. Elgohary
Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
Reumatismo
Systemic lupus erythematosus
lupus nephritis
interferon alpha (IFN-α).
title Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
title_full Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
title_fullStr Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
title_full_unstemmed Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
title_short Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
title_sort measurement of serum interferon alpha in egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity a case control study
topic Systemic lupus erythematosus
lupus nephritis
interferon alpha (IFN-α).
url https://www.reumatismo.org/index.php/reuma/article/view/1308
work_keys_str_mv AT afayed measurementofseruminterferonalphainegyptianpatientswithsystemiclupuserythematosusandevaluationofitseffectondiseaseactivityacasecontrolstudy
AT mmelmenyawi measurementofseruminterferonalphainegyptianpatientswithsystemiclupuserythematosusandevaluationofitseffectondiseaseactivityacasecontrolstudy
AT mghanema measurementofseruminterferonalphainegyptianpatientswithsystemiclupuserythematosusandevaluationofitseffectondiseaseactivityacasecontrolstudy
AT oshaker measurementofseruminterferonalphainegyptianpatientswithsystemiclupuserythematosusandevaluationofitseffectondiseaseactivityacasecontrolstudy
AT relgohary measurementofseruminterferonalphainegyptianpatientswithsystemiclupuserythematosusandevaluationofitseffectondiseaseactivityacasecontrolstudy